Taylor Rager

Taylor Rager

Auto-generated profile, based on publicly available information

Taylor Rager

Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
TRTaylor Rager
Taylor Rager
AEAdam Eckburg
Adam Eckburg
MPMeet Patel
Meet Patel
RQRong Qiu
Rong Qiu
SGShahina Gantiwala
Shahina Gantiwala
NPNeelu Puri
Neelu Puri
Melanoma possesses invasive metastatic growth patterns and is one of the most aggressive types of skin cancer. In 2021, it is estimated that 7180 deaths were attributed to melanoma in the United States alone. Once melanoma metastasizes, traditional therapies are no longer effective. Instead, immunotherapies, such as ipilimumab, pembrolizumab, and nivolumab, are the treatment options for malignant melanoma. Several biomarkers involved in tumorigenesis have been identified as potential targets for molecularly targeted melanoma therapy, such as tyrosine kinase inhibitors (TKIs). Unfortunately, melanoma quickly acquires resistance to these molecularly targeted therapies. To bypass resistance, combination treatment with immunotherapies and single or multiple TKIs have been employed and have been shown to improve the prognosis of melanoma patients compared to monotherapy. This review discusses several combination therapies that target melanoma biomarkers, such as BRAF, MEK, RAS, c-KIT, VEGFR, c-MET and PI3K. Several of these regimens are already FDA-approved for treating metastatic melanoma, while others are still in clinical trials. Continued research into the causes of resistance and factors influencing the efficacy of these combination treatments, such as specific mutations in oncogenic proteins, may further improve the effectiveness of combination therapies, providing a better prognosis for melanoma patients.

21 May 2024 in Cells
Verified
Journal Article
Open access
PDF file
Shreya DebShreya Deb
Shreya Deb
JBJoseph Berei
Joseph Berei
EMEdward Miliavski
Edward Miliavski
MKMuhammad J. Khan
Muhammad J. Khan
TBTaylor J. Broder
Taylor J. Broder
NPNeelu Puri
Neelu Puri
Telomeres, potential biomarkers of aging, are known to shorten with continued cigarette smoke exposure. In order to further investigate this process and its impact on cellular stress and inflammation, we used an in vitro model with cigarette smoke extract (CSE) and observed the downregulation of telomere stabilizing TRF2 and POT1 genes after CSE treatment. hTERT is a subunit of telomerase and a well-known oncogenic marker, which is overexpressed in over 85% of cancers and may contribute to lung cancer development in smokers. We also observed an increase in hTERT and ISG15 expression levels after CSE treatment, as well as increased protein levels revealed by immunohistochemical staining in smokers’ lung tissue samples compared to non-smokers. The effects of ISG15 overexpression were further studied by quantifying IFN-γ, an inflammatory protein induced by ISG15, which showed greater upregulation in smokers compared to non-smokers. Similar changes in gene expression patterns for TRF2, POT1, hTERT, and ISG15 were observed in blood and buccal swab samples from smokers compared to non-smokers. The results from this study provide insight into the mechanisms behind smoking causing telomere shortening and how this may contribute to the induction of inflammation and/or tumorigenesis, which may lead to comorbidities in smokers.

13 October 2022 in Journal of the Dermatology Nurses' Association
Verified
Journal Article
Closed access
TRTaylor Rager
Taylor Rager
ELEden Lake
Eden Lake
Mycosis fungoides is the most common primary cutaneous T-cell lymphoma. Although mycosis fungoides affects patients of all skin tones, mycosis fungoides has a higher incidence in patients with skin of color. Patients with skin of color who are diagnosed with mycosis fungoides have worse outcomes and poor prognosis compared with patients with lighter skin tones. Mycosis fungoides is difficult to diagnose in patients with skin of color as rare subtypes or clinical presentations are commonly seen in these populations. Increased awareness of the presentation of mycosis fungoides in skin of color and early detection could address the higher rates of morbidity and mortality in these populations.